Drug delivery strategies for poorly water-soluble drugs

• LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46:3-26.
   PubMed Web of Science ®Google Scholar
• GILIYAR C, FIKSTAD DT, TYAVANAGIMATT S: Challenges and opportunities in oral delivery of poorly water-soluble drugs. Drug Deliv. Technol. (2006) 6:57-63.
   Google Scholar
• LÖBENBERG R, AMIDON GL: Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. (2000) 50:3-20.
   PubMed Web of Science ®Google Scholar
• YU LX, AMIDON GL, POLLI JE et al.: Biopharmaceutics classification system: the scientific basis for biowaiver extension. Pharm. Res. (2002) 19:921-925.
   PubMed Web of Science ®Google Scholar
• POUTON CW: Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. (2006) 29:278-287.
   PubMed Web of Science ®Google Scholar
• KERNS EH, DI L: Pharmaceutical profiling in drug discovery. Drug Discov. Today (2003) 8:316-323.
   PubMed Web of Science ®Google Scholar
• MOGHIMI SM: Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anti-Cancer Agents in Med. Chem. (2006) 6:553-561.
   PubMed Web of Science ®Google Scholar
• CHIOU WL, RIEGELMAN S: Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. (1971) 60:1281-1302.
   PubMed Web of Science ®Google Scholar
• SEKIGUCHI K, OBI N: Absorption of eutectic mixtures. 1. A comparison of the behavior of a eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. (1961) 9:866-872.
   Web of Science ®Google Scholar
• GOLDBERG AH, GIBALDI M, KANIG JL: Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures II: Experimental evaluation of a eutectic mixture: Urea-acetaminophen system. J. Pharm. Sci. (1966) 55:482-487.
   Web of Science ®Google Scholar
• SERAJUDDIN ATM: Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. (1999) 88:1058-1066.
   PubMed Web of Science ®Google Scholar
• WANG L, CUI FD, SUNADA H: Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem. Pharm. Bull. (2006) 54:37-43.
   PubMed Web of Science ®Google Scholar
• BETAGERI GV, MAKARLA KR: Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int. J. Pharm. (1995) 126:155-160.
   Web of Science ®Google Scholar
• KUSHIDA I, ICHIKAWA M, ASAKAWA N: Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J. Pharm. Sci. (2002) 91:258-266.
   PubMed Web of Science ®Google Scholar
• BLOCH DW, SPEISER PP: Solid dispersions – fundamentals and examples. Pharm. Acta Helv. (1987) 62:23-27.
   Google Scholar
• HÜLSMANN S, BACKENSFELD T, KEITEL S, BODMEIER R: Melt extrusion–an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrate. Eur. J. Pharm. Biopharm. (2000) 49:237-242.
   PubMed Web of Science ®Google Scholar
• VERRECK G, SIX K, VAN DEN MOOTER G et al.: Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion–Part I. Int. J. Pharm. (2003) 251:165-174.
   PubMed Web of Science ®Google Scholar
• RAMBALI B, VERRECK G, BAERT L, MASSART DL: Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. (2003) 29:641-652.
   PubMed Web of Science ®Google Scholar
• CRAIG DQM: The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. (2002) 231:131-144.
   PubMed Web of Science ®Google Scholar
• DOUROUMIS D, BOUROPOULOS N, FAHR A: Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method. J. Pharm. Pharmacol. (2007) 59:1-9.
   Web of Science ®Google Scholar
• DUCHENE D, WOUESSIDJEWE D, PONCHEL G: Cyclodextrins and carrier systems. J. Control. Release (1999) 62:263-268.
   PubMed Web of Science ®Google Scholar
• LOFTSSON T, BREWSTER ME: Pharmaceutical applications of cyclodextrin. 1. Drug solubilization and stabilization. J. Pharm. Sci. (1996) 85:1017-1025.
   PubMed Web of Science ®Google Scholar
• MCCORMACK B, GREGORIADIS G: Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int. J. Pharm. (1998) 162:59-69.
   Web of Science ®Google Scholar
• SZENTE L, SZEJTLI J: Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. (1999) 36:17-28.
   PubMed Web of Science ®Google Scholar
• RAJEWSKI RA, STELLA VJ: Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. (1996) 85:1142-1169.
   PubMed Web of Science ®Google Scholar
• STELLA VJ, RAJEWSKI RA: Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. (1997) 14:556-567.
   PubMed Web of Science ®Google Scholar
• BECKET G, SCHEP LJ, TAN MY: Improvement of the in vitro dissolution of praziquantel by complexation with α-, β- and γ-cyclodextrins Int. J. Pharm. (1999) 179:65-71.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Itraconazole in cyclodextrin solution. Pharmacotherapy (1999) 19:603-611.
   PubMed Web of Science ®Google Scholar
• NAGASE Y, HIRATA M, WADA K et al.: Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin. Int. J. Pharm. (2001) 229:163-172.
   PubMed Web of Science ®Google Scholar
• PANINI R, VANDELLI MA, FORNI F, PRADELLI JM, SALVIOLI G: Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropylβ -cyclodextrin complexation in healthy volunteers. Pharm. Res. (1995) 31:205-209.
   Google Scholar
• VEIGA MD, AHSAN F: Solubility study of tolbutamide in monocomponent and dicomponent solutions of water. Int. J. Pharm. (1998) 160:43-49.
   Web of Science ®Google Scholar
• AMMAR HO, SALAMA HA, GHORAB M, MAHMOUD AA: Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems. Int. J. Pharm. (2006) 309:129-138.
   PubMed Web of Science ®Google Scholar
• AMMAR HO, SALAMA HA, GHORAB M, MAHMOUD AA: Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy. Int. J. Pharm. (2006) 320:53-57.
   PubMed Web of Science ®Google Scholar
• LOFTSSON T, JARHO P, MÁSSON M, JÄRVINEN T: Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. (2005) 2:335-351.
   PubMed Web of Science ®Google Scholar
• HUMBERSTONE AJ, CHARMAN WN: Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Del. Rev. (1997) 25:103-128.
   Web of Science ®Google Scholar
• CHAKRABARTI S, BELPAIRE FM: Bioavailability of phenytoin in lipid containing dosage forms in rats. J. Pharm. Pharmacol. (1978) 30:330-331.
   PubMed Web of Science ®Google Scholar
• CARRIGAN PJ, BATES TR: Biopharmaceutics of drugs administered in lipid-containing dosage forms 1: GI absorption of griseofulvin from an oil-in-water emulsion in the rat. J. Pharm. Sci. (1973) 62:1476-1479.
   PubMed Web of Science ®Google Scholar
• BATES TR, SEQUEIRA JA: Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J. Pharm. Sci. (1975) 64:793-797.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN KL, PEDERSEN GP, KRISTENSEN HG: Preparation of redispersible dry emulsions by spray drying. Int. J. Pharm. (2001) 212:187-194.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN KL, PEDERSEN GP, KRISTENSEN HG: Technical optimisation of redispersible dry emulsions. Int. J. Pharm. (2001) 212:195-202.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI H, SASAKI H, NIWA T et al.: Redispersible dry emulsion system as novel oral dosage form of oily drugs: In vivo studies in beagle dogs. Chem. Pharm. Bull. (1991) 39:3362-3364.
   PubMed Web of Science ®Google Scholar
• DOLLO G, LE CORRE P, GUERIN A et al.: Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur. J. Pharm. Sci. (2003) 19:273-280.
   PubMed Web of Science ®Google Scholar
• HANSEN T, HOLM P, SCHULTZ K: Process characteristics and compaction of spray-dried emulsions containing a drug dissolved in lipid. Int. J. Pharm. (2004) 287:55-66.
   PubMed Web of Science ®Google Scholar
• HANSEN T, HOLM P, ROHDE M, SCHULTZ K: In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int. J. Pharm. (2005) 293:203-211.
   PubMed Web of Science ®Google Scholar
• CONSTANTINIDES PP, TUSTIAN A, KESSLER DR: Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Del. Rev. (2004) 56:1243-1255.
   PubMed Web of Science ®Google Scholar
• CONSTANTINIDES PP, HAN J, DAVIS SS: Advances in the use of tocols as drug delivery vehicles. Pharm. Res. (2006) 23:243-255.
   PubMed Web of Science ®Google Scholar
• VON CORSWANT C, THOREN P, ENGSTRÖM S: Triglyceride-based microemulsion for intravenous administration of sparingly soluble substances. J. Pharm. Sci. (1998) 87:200-208.
   PubMed Web of Science ®Google Scholar
• CONSTANTINIDES PP, LAMBERT KJ, TUSTIAN AK et al.: Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. (2000) 17:175-182.
   PubMed Web of Science ®Google Scholar
• COLLINS-GOLD LC, LYONS RT, BARTHOLOW LC: Parenteral emulsions for drug delivery. Adv. Drug Del. Rev. (1990) 5:189-208.
   Google Scholar
• LAWRENCE MJ, REES GD: Microemulsion-based media as novel drug delivery system. Adv. Drug Del. Rev. (2000) 45:89-121.
   PubMed Web of Science ®Google Scholar
• DANIELSSON I, LINDMAN B: The definition of microemulsion. Colloids and Surfaces (1981) 3:391-392.
   Web of Science ®Google Scholar
• SHINODA K, LINDMAN B: Organized surfactant system: microemulsions. Langmuir (1987) 3:135-149.
   Web of Science ®Google Scholar
• GAO ZG, CHOI HG, SHIN HJ et al.: Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int. J. Pharm. (1998) 161:75-86.
   Web of Science ®Google Scholar
• ITOH K, MATSUI S, TOZUKA Y, OGUCHI T, YAMAMOTO K: Improvement of physicochemical properties of N-4472. Part II: characterization of N-4472 microemulsion and the enhanced oral absorption. Int. J. Pharm. (2002) 246:75-83.
   PubMed Web of Science ®Google Scholar
• ARAYA H, TOMITA M, HAYASHI M: The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int. J. Pharm. (2005) 305:61-74.
   PubMed Web of Science ®Google Scholar
• LI P, GHOSH A, WAGNER RF et al.: Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. Int. J. Pharm. (2005) 288:27-34.
   PubMed Web of Science ®Google Scholar
• KANG BK, LEE JS, CHON SK et al.: Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. (2004) 274:65-73.
   PubMed Web of Science ®Google Scholar
• IWANAGA K, KUSHIBIKI T, MIYAZAKI M, KAKEMI M: Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs. Biol. Pharm. Bull. (2006) 29:508-512.
   PubMed Web of Science ®Google Scholar
• CHANDRA SEKHARA RAO G, SATISH KUMAR M, MATHIVANAN N, BHANOJI RAO ME: Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie (2003) 59:5-9.
   Web of Science ®Google Scholar
• KOCBEK P, BAUMGARTNER S, KRISTL J: Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. (2006) 312:179-186.
   PubMed Web of Science ®Google Scholar
• MÜLLER RH, JACOBS C, KAYSER O: Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Del. Rev. (2001) 47:3-19.
   PubMed Web of Science ®Google Scholar
• WESTESEN K: Novel lipid-based colloidal dispersions as potential drug administration systems – expectations and reality. Colloid Polym. Sci. (2000) 278:608-618.
   Web of Science ®Google Scholar
• DEBUIGNE F, CUISENAIRE J, JEUNIEAU L, MASEREEL B, NAGY JB: Synthesis of nimesulide nanoparticles in the microemulsion epikuron/isopropyl myristate/water/n-butanol (or isopropanol). J. colloid Interface Sci. (2001) 243:90-101.
   Web of Science ®Google Scholar
• GASSMANN P, LIST M, SCHWEITZER A, SUCKER H: Hydrosols – Alternatives for the parenteral application of poorly water soluble drugs. Eur. J. Pharm. Biopharm. (1994) 40(2):64-72.
   Web of Science ®Google Scholar
• TROTTA M, GALLARATE M, PATTARINO F, MOREL S: Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J. Control. Release (2001) 76:119-128.
   PubMed Web of Science ®Google Scholar
• LIVERSIDGE GG, CONZENTINO P: Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. (1995) 125:309-313.
   Web of Science ®Google Scholar
• PETERS K, LEITZKE S, DIEDERICHS JE et al.: Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. (2000) 45:77-83.
   PubMed Web of Science ®Google Scholar
• MÖSCHWITZER J, ACHLEITNER G, POMPER H, MÜLLER RH: Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. (2004) 58:615-619.
   PubMed Web of Science ®Google Scholar
• KIPP JE: The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. (2004) 284:109-122.
   PubMed Web of Science ®Google Scholar
• MERISKO-LIVERSIDGE E, SARPOTDAR P, BRUNO J et al.: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. (1996) 13:272-278.
   PubMed Web of Science ®Google Scholar
• MERISKO-LIVERSIDGE E, LIVERSIDGE GG, COOPER ER: Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. (2003) 18:113-120.
   PubMed Web of Science ®Google Scholar
• FAHR A, HOLZ M, FRICKER G: Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics. Pharm. Res. (1995) 12(8):1189-1198.
   PubMed Web of Science ®Google Scholar
• KAYSER O, OLBRICH C, YARDLEY V, KIDERLEN AF, CROFT SL: Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. (2003) 254:73-75.
   PubMed Web of Science ®Google Scholar
• YANG S, LU L, CAI Y et al.: Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release (1999) 59:299-307.
   PubMed Web of Science ®Google Scholar
• DEMIREL M, YAZAN Y, MÜLLER RH, KILIC F, BOZAN B: Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J. Microencapsul. (2001) 18:359-371.
   PubMed Web of Science ®Google Scholar
• YANG S, ZHU J, LU Y, LIANG B, YANG C: Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. (1999) 16:751-757.
   PubMed Web of Science ®Google Scholar
• MÜLLER RH, KECK CM: Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechol. (2004) 113:151-170.
   PubMed Web of Science ®Google Scholar
• PORTER CJH, CHARMAN WN: In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. (2001) 50:S127-S147.
   PubMed Web of Science ®Google Scholar
• CHARMAN WN: Lipids, lipophilic drugs, and oral drug delivery – some emerging concepts. J. Pharm. Sci. (2000) 89:967-978.
   PubMed Web of Science ®Google Scholar
• MEHNERT W, MÄDER K: Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug. Deliv. Rev. (2001) 47:165-196.
   PubMed Web of Science ®Google Scholar
• MÜLLER RH, MAAßEN S, WEYHERS H, MEHNERT W: Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407. J. Drug Target (1996) 4:161-170.
   PubMed Web of Science ®Google Scholar
• MÜLLER RH, MAAßEN S, WEYHERS H, SPECHT F, LUCKS JS: Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. (1996) 138:85-94.
   Web of Science ®Google Scholar
• FREITAS C, MÜLLER RH: Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. Int. J. Pharm. (1998) 168:221-229.
   Web of Science ®Google Scholar
• FREITAS C, MÜLLER RH: Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. (1999) 47:125-132.
   PubMed Web of Science ®Google Scholar
• DINGLER A, GOHLA S: Production of solid lipis nanoparticles (SLN): scaling up feasibilities. J. Microencapsul. (2002) 19:11-16.
   PubMed Web of Science ®Google Scholar
• GOHLA SH, DINGLER A: Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie (2001) 56:61-63.
   PubMed Web of Science ®Google Scholar
• UGAZIO E, CAVALLI R, GASCO MR: Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. (2002) 241:341-344.
   PubMed Web of Science ®Google Scholar
• MÜLLER RH, RUNGE S, RAVELLI V et al.: Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm. (2006) 317:82-89.
   PubMed Web of Science ®Google Scholar
• LUO Y, CHEN D, REN L, ZHAO X, QIN J: Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability J. Control. Release (2006) 114:53-59.
   PubMed Web of Science ®Google Scholar
• GOUNDALKAR A, MEZEI M: Chemical modification of triamcinolone acetonide to improve liposomal encapsulation. J. Pharm. Sci. (1983) 73:834-835.
   Web of Science ®Google Scholar
• FRESTA M, VILLARI A, PUGLISI G, CAVALLARO G: 5-Fluorouracil: various kinds of loaded liposomes: encapsulation efficiency, storage stability and fusogenic properties. Int. J. Pharm. (1993) 99:145-156.
   Web of Science ®Google Scholar
• OLSON F, MAYHEW E, MASLOW D, RUSTUM Y, SZOKA F: Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. (1982) 18:167-176.
   PubMedGoogle Scholar
• GABIZON A, DAGAN A, GOREN D, BARENHOLZ Y, FUKS Z: Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. (1982) 42:4734-4739.
   PubMed Web of Science ®Google Scholar
• MOHAMMED AR, WESTON N, COOMBES AGA, FITZGERALD M, PERRIE Y: Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int. J. Pharm. (2004) 285:23-34.
   PubMed Web of Science ®Google Scholar
• WATERHOUSE DN, MADDEN TD, CULLIS PR et al.: Preparation, characterization, and biological analysis of liposomal formulations of Vincristine. Methods Enzymol. (2005) 391:40-57.
   PubMed Web of Science ®Google Scholar
• FAHR A, SEELIG J: Liposomal formulations of cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics. Crit. Rev. Ther. Drug Carrier Sys. (2001) 18(2):141-172.
   PubMed Web of Science ®Google Scholar
• SCHOTE U, GANZ P, FAHR A, SEELIG J: Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J. Pharm. Sci. (2002) 91(3):856-867.
   PubMed Web of Science ®Google Scholar
• FAHR A, VAN HOOGEVEST P, MAY S, BERGSTRAND N, ML SL: Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. (2005) 26(3-4):251-265.
   PubMed Web of Science ®Google Scholar
• DUPONT B: Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. (2002) 49(Suppl. S1):31-36.
   PubMed Web of Science ®Google Scholar
• WONG BERINGER A, JACOBS RA, GUGLIELMO J: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27(3):603-618.
   PubMed Web of Science ®Google Scholar
• PODA GI, TETKO IV, ROHRER DC: Towards predictive ADME profiling of drug candidates: lipophilicity and solubility. 229th American Chemical Society National Meeting & Exposition; ACS. San Diego, CA 2005.
   Google Scholar
• TETKO IV, BRUNEAU P: Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. J. Pharm. Sci. (2004) 93:3103-3110.
   PubMed Web of Science ®Google Scholar
• ILLUM L, WASHINGTON C, LAWRENCE S, WATTS P: Lipid vehicle drug delivery composition containing Vitamin E. In. UK: Danbiosyst UK Limited (1997):1-44.
   Google Scholar
• JENNING V, SCHÄFER-KORTING M, GOHLA S: Vitamin-A loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release (2000) 66:115-126.
   PubMed Web of Science ®Google Scholar
• JORES K, MEHNERT W, MÄDER K: Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. (2003) 20:1274-1283.
   PubMed Web of Science ®Google Scholar
• ÜNER M, WISSING SA, YENER G, MÜLLER RH: Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for application of ascorbyl palmitate. Pharmazie (2005) 60:577-582.
   PubMed Web of Science ®Google Scholar
• LEUNER G, DRESSMAN J: Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. (2000) 50:40-60.
   Google Scholar
• SUCKER H: Hydrosole, eine alternative für die parenterale anwendung von schwer wasserlöslichen Wirkstoffen. In: Pharmazeutische Technologie –Moderne Darreichungsformen. Müller RH et al. (Eds), WVG, Stuttgart, Germany (1998):383-392.
   Google Scholar

Website

• http://www.fda.gov/cder/OPS/BCS_guidance.htm US Food and Drug Administration. Center for Drug Evaluation and Research. The Biopharmaceutics Classification System (BCS) Guidance.
   Google Scholar